Trial Profile
Phase II a Randomized Study of Iodine-131 Anti-b1 Antibody Versus Anti-b1 Antibody in Chemotherapy-relapsed/Refractory Low-grade or Transformed Low-grade Non-Hodgkin's Lymphoma.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 29 Oct 2023
Price :
$35
*
At a glance
- Drugs Iodine-131 tositumomab (Primary) ; Tositumomab
- Indications Non-Hodgkin's lymphoma
- Focus Therapeutic Use
- Sponsors GlaxoSmithKline; GSK
- 17 Apr 2012 New trial record